See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Veiko Vasar

https://www.etis.ee/CV/Veiko_Vasar/est
16.01.1956
7.03.2015

Teenistuskäik

Töökohad ja ametid
01.01.2000–...   
SA TÜ Kliinikum, psühhiaatriakliinik, kliiniku juhataja
01.09.2004–31.08.2009   
Tartu Ülikool, Arstiteaduskond, Psühhiaatriakliinik, psühhiaatria professor (1,00)
1999–2004   
Tartu Ülikool, Arstiteaduskond, Psühhiaatriakliinik, Professor (1,00)
01.01.1997–31.12.1999   
Tartu Psühhiaatriakliinik, ülemarst
01.01.1995–31.12.1997   
Tartu Psühhiaatriakliinik, peaarst
1990–1999   
Tartu Ülikool, Arstiteaduskond, Psühhiaatriakliinik, Dotsent (1,00)
01.01.1990–31.12.1991   
Helsinki Ülikool, psühhiaatriakliinik, külalisteadur
1985–1990   
Tartu Ülikool, Arstiteaduskond, Psühhiaatriakliinik, Assistent (1,00)
1980–1985   
Tartu Ülikool, Arstiteaduskond, Psühhiaatriakliinik, Teadur (1,00)
 
 
Haridustee
1973–1979   
Tartu Ülikool, Arstiteaduskond
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2002−...   
Sotsiaalministeeriumi psühhiaatria erialakomisjoni liige
1992−...   
TÜ arstiteaduskonna nõukogu liige
1992−...   
Éesti Psühhiaatrite Selts, juhatuse liige, aseesimees
2003−2006   
Eesti Teadusfondi nõukogu liige, arstiteaduste ekspertkomisjoni esimees
2001−2003   
Tartu Ülikooli nõukogu liige

Kvalifikatsioon

Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; TÄPSUSTUS: Une-, ärevus- ja meeleoluhäirete neurobioloogia Ärevus- ja meeleoluhäirete epidemioloogia ning nendega seotud psühhosotsiaalsed tegurid
 
 
Lisainfo
meditsiinikandidaat
Tartu Ülikool, 1987

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2012
Tõru, I.; Maron, E.; Raag, M.; Vasar, V.; Nutt, D.J.; Shlik, J. (2012). The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers. European Neuropsychopharmacology, 23 (7), 645−652.10.1016/j.euroneuro.2012.08.011.
1.1.
2012
Koido, Kati; Traks, Tanel; Balõtšev, Roman; Eller, Triin; Must, Anne; Kõks, Sulev; Maron, Eduard; Tõru, Innar; Shlik, Jakov; Vasar, Veiko; Vasar, Eero (2012). Associations between LSAMP gene polymorphisms and major depressive disorder and panic disorder. Translational Psychiatry, 2, 1−5.10.1038/tp.2012.74.
5.2.
2012
Luuk, Kersti; Aluoja, Anu; Vasar, Veiko (2012). Childhood adversity and anxiety and depressive symptoms in adulthood: The mediating role of locus of control.
1.1.
2011
Maron, E.; Toru, I.; Hirvonen, J.; Tuominen, L.; Lumme, .V; Vasar, V.; Shlik, J.; Nutt, D.J.; Helin, S.; Någren, K.; Tiihonen, J.; Hietala, J. (2011). Gender differences in brain serotonin transporter availability in panic disorder. Journal of Psychopharmacology, 25 (7), 952−959.10.1177/0269881110389207.
1.3.
2011
Klienberg, A.; Jaanson, P.; Lehtmets, A.; Aluoja, A.; Vasar, V.; Suija, K.; Ööpik, P. (2011). Depressiooni ravijuhend perearstidele. Eesti Arst, 90 (9), 431−446.
5.2.
2011
Vaher, H.; Veldi, M.; Eller, T.; Kasenõmm, P.; Vasar, V. (2011). The predictive value of pediatric sleep health on pediatric behavior. Sleep Medicine, 12. Suppl.1, S129.
5.2.
2011
Veldi, M.; Vaher, H.; Tamm, M.; Torma, T.; Eller, T.; Vasar, V. (2011). Effect of contineous airway pressure treatment on sympathetic nervous activity and daytime function in patients with obstructive sleep apnea. Sleep Medicine, 12. Suppl. 1, S106.
6.6.
2011
Klienberg, A.; Jaanson, P.; Lehtmets, A.; Aluoja, A.; Vasar, V.; Suija, K.; Ööpik, P. (2011). Depressiooni ravijuhis perearstidele. Perearst, 63 (9), 22−64.
1.1.
2010
Kleinberg, A.; Aluoja, A.; Vasar, V. (2010). Point prevalence of major depression in Estonia. Results from the 2006 Estonian Health Survey. European Psychiatry, 25 (8), 485−490.10.1016/j.eurpsy.2010.06.005.
1.1.
2010
Tõru, I.; Aluoja, A.; Võhma, Ü.; Raag, M.; Vasar, V.; Maron, E.; Shlik, J. (2010). Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Psychiatry Research, 178 (2), 342−347.10.1016/j.psychres.2010.04.003.
1.1.
2010
Võhma, Ü.; Aluoja, A.; Vasar, V.; Shlik, J.; Maron, E. (2010). Evaluation of personality traits in panic disorder using Swedish universities Scales of Personality. Journal of Anxiety Disorders, 24 (1), 141−146.
1.1.
2010
Eller, T; Metsküla, K; Talja, I; Maron, E; Uibo, R; Vasar, V. (2010). Thyroid autoimmunity and treatment response to escitalopram in major depression. Nordic Journal of Psychiatry, x−x.
1.1.
2010
Koido, K.; Eller, T.; Kingo, K.; Kõks, S.; Traks, T.; Shlik, J.; Vasar, V; Vasar, E.; Maron, E. (2010). Interleukin 10 family gene polymorphisms are not associated with major depressive disorder and panic disorder phenotypes. Journal of Psychiatric Research, 44 (5), 275−277.10.1016/j.jpsychires.2009.09.001.
1.1.
2010
Maron, E.; Kallassalu, K.; Tammiste, A.; Kolde, R.; Vilo, J.; Tõru, I.; Vasar, V.; Shlik, J.; Metspalu, A. (2010). Peripheral Gene Expression Profiling of CCK-4-Induced Panic in Healthy Subjects. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics, 153B (1), 269−274.10.1002/ajmg.b.30898.
1.2.
2010
Veldi, M.; Ani, R.; Vaher, H.; Eller, T.; Hion, T.; Aluoja, A.; Vasar, V. (2010). Obstructive sleep apnea syndrome (OSAS): Pathophysiology in Estonians. Pathophysiology, 17 (3), 219−223. DOI: 10.1016/j.pathophys.2010.01.001.
1.3.
2010
Maron, E.; Eller, T.; Vasar, V. (2010). Bupropioonravi depressiooni korral: mono- ja kombinatsioonteraapia. Eesti Arst, 89, 113−119.
1.3.
2010
Eller, T.; Maron, E.; Vasar, V. (2010). Depressioon, antidepressantravi ja tsütokiinid. Eesti Arst, 825−832.
1.3.
2010
Vaher, H; Veldi, M; Müürsepp, P; Kasenõmm, P; Vasar, V. (2010). Obstruktiivse uneapnoe sündroomi riskitegurid võivad pärineda lapse- ja noorukieast. Haigusjuhu kirjeldus. Eesti Arst, 746−750.
5.2.
2010
Maron, E., Tõru, I., Hirvonen, J., Vasar, V., Shlik, J., Nutt, D.J., Tiihonen, J., Hietala, J. (2010). Brain serotonin transporter availability in panic disorder: Gender differences and implications for treatment response to escitalopram. In: (45−45).27th CINP Congress; Hong Kong 2010-06-06 to 2010-06-10. Elsevier.
1.1.
2009
Eller, T.; Aluoja, A.; Maron, E.; Vasar, V. (2009). Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina-Lithuania, 45 (12), 971−977.
1.1.
2009
Maron, E.; Eller, T.; Vasar, V.; Nutt, D.J. (2009). Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. Journal of Clinical Psychiatry, 70 (7), 1054−1056.
1.1.
2009
Eller, T.; Vasar, V.; Shlik, J.; Maron, E. (2009). The role of IL-2 and soluble IL-2R in depression and antidepressant response. Current Opinion in Investigational Drugs, 10 (7), 638−643.
1.1.
2009
Maron, E.; Tammiste, A.; Kallassalu, K.; Eller, T.; Vasar, V.; Nutt, D.J.; Metspalu, A. (2009). Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European Neuropsychopharmacology, 19, 6, 451−456.
1.1.
2009
Maron, E.; Tõru, I.; Mäemets, K.; Sepp, S.; Vasar, V.; Shlik, J.; Zharkovski, A. (2009). CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects. Journal of Psychopharmacology, 23 (4), 460 −464. DOI: 10.1177/0269881108089600.
1.3.
2009
Maron, E; Eller, T; Nutt, D; Vasar, V. (2009). Bupropiooni augmentatsiooni toime estsitalopraamravi suhtes resistentsetel depressiivsetel patsientidel. Eesti Arst, 88, 82−90.
5.2.
2009
Vaher, H.; Vasar, V.; Ani, R.; Veldi, M. (2009). Treatment of sleepapnea in cases of Prader-Willi syndrome. Sleep Medicine, 10. p. S43. (2).
1.1.
2008
Traks, T.; Koido, K.; Eller, T.; Maron, E.; Kingo, K.; Vasar, V.; Vasar, E.; Kõks, S. (2008). Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder. BMC Medical Genetics, 9, 111. DOI: 10.1186/1471-2350-9-111.
1.1.
2008
Maron, E.; Tõru, I.; Tasa, G.; Must, A.; Toover, E.; Lang, A.; Vasar, V.; Shlik, J. (2008). Association testing of panic disorder candidate genes using Cck-4 challenge in healthy volunteers. Neuroscience Letters, 446, 88−92. DOI: 10.1016/j.neulet.2008.09.052.
1.1.
2008
Eller, T.; Vasar, V.; Shlik3, J.; Maron, E. (2008). Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32 (2), 445−450. DOI: 10.1016/j.pnpbp.2007.09.015.
1.2.
2008
Veldi, M.; Vain, A.; Vasar, V.; Kull, M.; Partinen, M. (2008). Restless legs syndrome (RLS) and muscular tone of tibial muscle. Sleep and Biological Rhythms, 6 (4), 242−248. DOI: 10.1111/j.1479-8425.2008.00365.x.
1.3.
2008
Kõrv, J.; Linnamägi, Ü.; Asser, T.; Vasar, V.; Eamets, R.; Sobocki, P. (2008). Kui suured on kulutused peaajuhaigustele Eestis? Eesti Arst, 87 (5), 347−355.
1.1.
2007
Maron, E.; Tõru, I.; Must, A.; Tasa, G.; Toover, E.; Vasar, V.; Lang, A.; Shlik, J. (2007). Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. Neuroscience Letters, 411 (3), 180−184.
5.1.
2007
Maron, E., Yuan, P., Tõru, I., Vasar, V., Neumeister, A., Shlik, J., Manji, H. (2007). Associations between plasma BDNF and CCK-4 challenge in healthy subjects. European neuropsychopharmacology, 17: ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe Nice, FRANCE, MAR 08-11, 2007. Elsevier, 8−9. (Suppl. 1).
5.2.
2007
Eller, T.; Metsküla, K.; Talja, I.; Vasar, V.; Uibo, R. (2007). Uurimus autoantikehade esinemisest depressiivsetel haigetel. Eesti Arst, 86 (9), 672−673.
5.2.
2007
Veldi, M.; Eller, T.; Hion, T.; Pindmaa, M.; Ani, R.; Kull, M.; Partinen, M.; Vasar, V. (2007). Ageing, sleep apnea, upper airway disorders, cardiac disorders, and symptoms of depression. Sleep Medicine, 8, S87.
5.2.
2007
Veldi, M.; Partinen, M.; Torma, T.; Vasar, V.; Kull, M. (2007). Nocturnal groaning: parasomnia related to REM-sleep. Sleep Medicine, 8, S87.
5.2.
2007
Veldi, M.; Vain, A.; Vasar, V.; Kull, M.; Partinen, M. (2007). Restless legs syndrome and changes of muscular tone. Sleep Medicine, 8, S86.
5.2.
2007
Veldi, M.; Hion, T.; Vasar, V.; Kull, M. (2007). Quality of life and driving ability in sleep apnoea patients before and after CPAP treatment - evaluation by sleep and daytime habits questionnaire and divided attention steering simulator (DASS). Sleep and Biological Rhythms, 5, A6.
1.1.
2006
Eller, T.; Aluoja, A.; Vasar, V.; Veldi, M. (2006). Symptoms of anxiety and depression in Estonian medical students with sleep problems. Depression and Anxiety, 23 (4), 250−256.
1.1.
2006
Tõru, I.; Shlik, J.; Maron, E.; Vasar, V.; Nutt, D. (2006). Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology, 186 (1), 107−112.
1.1.
2006
Koks, S.; Nikopensius, T.; Koido, K.; Maron, E.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Kurg, A.; Shlik, J.; Vasar, V.; Metspalu, A.; Vasar, E. (2006). Analysis of SNP profiles in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 9 (2), 167−174.
5.1.
2006
Maron, E.; Koido, K.; Must, A.; Reimets, A.; Kõks, S.; Vasar, E.; Vasar, V.; Shlik, J. (2006). Association study of limbic system-associated membrane protein gene polymorphisms in panic disorder. European neuropsychopharmacology, 16 (Suppl. 4). 459−460.
1.1.
2005
Maron, E.; Lang, A.; Tasa, G.; Liivlaid, L.; Toru, I.; Must, A.; Vasar, V.; Shlik, J. (2005). Associations between serotonin-related gene polymorphisms and panic disorder. International Journal of Neuropsychopharmacology, 8 (2), 261−266.
1.1.
2005
Veldi, M.; Aluoja, A.; Vasar, V. (2005). Sleep quality and more common sleep-related problems in medical students. Sleep Medicine, 6 (3), 269−275.
1.1.
2005
Maron, E.; Nikopensius, T.; Koks, S.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Koido, K.; Kurg, A.; Metspalu, A.; Vasar, E.; Vasar, V.; Shlik, J. (2005). Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatric Genetics, 15 (1), 17−24.
1.1.
2005
Koido, K.; Kõks, S.; Nikopensius, T.; Maron, E.; Altmäe, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Kurg, A.; Shlik, J.; Vasar, V.; Metspalu, A.; Vasar, E. (2005). Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. International Journal of Neuropsychopharmacology, 8 (2), 235−244.
3.1.
2005
Veldi, M.; Vasar, V.; Vain, A.; Torma, T.; Kull, M. (2005). Impact of CPAP Treatment on the Muscular Tone of the Tongue. In: Penzel, T.; Fietze, I.; Chokroverty, S. (_EditorsAbbr). Proceedings of the World Association of Sleep Medicine 1st Congress (111−114).. Bologna, Italy: MEDIMOND S.r.l..
5.1.
2005
Maron, E.; Koks, S.; Nikopensius, T.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Koido, K.; Kurg, A.; Shlik, J.; Vasar, V.; Metspalu, A.; Vasar, E. (2005). Association and haplotype analaysis of 90 single-nucleotide polymorphisms in mood disorders. European Neuropsychopharmacology, 15, S55−S56.
5.2.
2005
Eller, T.; Aluoja, A.; Vasar, V.; Veldi, M. (2005). Depressiooni ja ärevuse sümptomid seoses uneprobleemidega eesti arstiüliõpilastel. Eesti Arst, 9, 655.
1.1.
2004
Aluoja, A.; Leinsalu, M.; Shlik, J.; Vasar, V.; Luuk, K. (2004). Symptoms of depression in the Estonian population: prevalence, sociodemographic correlates and social adjustment. Journal of Affective Disorders, 78 (1), 27−35.
1.1.
2004
Maron, E.; Tasa, G.; Toru, I.; Lang, A.; Vasar, V.; Shlik, J. (2004). Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. World Journal of Biological Psychiatry, 5 (3), 149−154.
1.1.
2004
Maron, E.; Kuikka, JT.; Shlik, J.; Vasar, V.; Vanninen, E.; Tiihonen, J. (2004). Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Research-Neuroimaging, 132 (2), 173−181.
1.1.
2004
Shlik, J.; Maron, E.; Toru, I.; Aluoja, A.; Vasar, V. (2004). Citalopram challenge in social anxiety disorder. International Journal of Neuropsychopharmacology, 7 (2), 177−182.
1.1.
2004
Maron, E.; Toru, I.; Vasar, V.; Shlik, J. (2004). The effect of 5-hydroxytryptophan on chotecystokinin-4-induced panic attacks in healthy volunteers. Journal of Psychopharmacology, 18 (2), 194−199.
1.1.
2004
Maron, E.; Kuikka, JT.; Ulst, K.; Tiihonen, J.; Vasar, V.; Shlik, J. (2004). SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. European Archives of Psychiatry and Clinical Neuroscience, 254 (6), 392−396.
1.2.
2004
Veldi, M.; Vasar, V.; Vain, A.; Kull, M. (2004). Obstructive sleep apnea and ageing: Myotonometry demonstrates changes in the soft palate and tongue while awake. Pathophysiology, 11 (3), 159−165.
1.3.
2004
Veldi, M.; Aluoja, A.; Vasar, V. (2004). Une kvaliteet ja sagedasemad unehäired arstiteaduskonna üliõpilastel. Eesti Arst, 83 (2), 76−80.
1.3.
2004
Aluoja, A.; Slik, J.; Vasar, V. (2004). Depressioon ja sotsiaalne toimimine. Eesti Arst, 83 (4), 241−246.
5.1.
2004
Maron, E.; Tasa, G.; Toru, I.; Lang, A.; Vasar, V.; Shlik, J. (2004). Association between serotonin-related genetic polymorphisms and cholecystokinin tetrapeptide induced panic attacks in healthy volunteers. European Neuropsychopharmacology, 14, S125−S126.
5.1.
2004
Maron, E.; Tasa, G.; Toru, I.; Lang, A.; Vasar, V.; Shlik, J. (2004). Association between serotonin-related genetic polymorphisms and cholecystokinin tetrapeptide induced panic attacks in healthy volunteers. European Neuropsychopharmacology, 14, S14−S15.
5.1.
2004
Maron, E.; Nikopensius, T.; Koks, S.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Koido, K.; Kurg, A.; Metapalu, A.; Vasar, E.; Vasar, V.; Shlik, J. (2004). Association study of 90 candidate genetic polymorphisms in panic disorder: Positive findings with SNPs in serotonin, cholecystokinin and dopamine related genes. European Neuropsychopharmacology, 14, S317−S317.
5.2.
2004
Veldi, M.; Aluoja, A.; Vasar, V. (2004). Sleep quality and more common sleep-related problems in medical students. Journal of Sleep Research, 13, 770.
5.1.
2003
Maron, E.; Kuikka, JT.; Shlik, J.; Vasar, V.; Vanninen, E.; Tiihonen, J. (2003). Reduced brain serotonin transporter binding in patients with panic disorder. European Neuropsychopharmacology, 13, S358−S359.
1.1.
2002
Veldi, M.; Vasar, V.; Hion, T.; Vain, A.; Kull, M. (2002). Myotonometry demonstrates changes of lingual musculature in obstructive sleep apnoea. European Archives of Oto-Rhino-Laryngology, 259 (2), 108−112.
5.1.
2002
Shlik, J.; Maron, E.; Aluoja, A.; Vasar, V.; Toru, I. (2002). Citalopram challenge in social anxiety disorder. European Neuropsychopharmacology, 12, S339−S340.
6.3.
2002
Kull, M.; Veldi, M.; Vasar, V.; Hion, T. (2002). Obstruktiivse uneapnoe hetkeseis: diagnostika ja ravi põhimõtted. Lege Artis, 5 (9), 26−29.
1.1.
2001
Pakriev, S.; Shlik, J.; Vasar, V. (2001). Course of depression: Findings from a cross-sectional survey in rural Udmurtia. Nordic Journal of Psychiatry, 55 (3), 185−189.
1.1.
2001
Veldi, M.; Vasar, V.; Hion, T.; Kull, M.; Vain, A. (2001). Ageing, soft-palate tone and sleep-related breathing disorders. Clinical Physiology, 21 (3), 358−364.
1.3.
2001
Veldi, M.; Vasar, V.; Hion, T.; Eller, T.; Shlik , J.; Kull , M. (2001). Vanus ja uneapnoehaigus – riskitegurid ja päevased kaebused. Eesti Arst, 80 (8), 325−328.
5.2.
2001
Veldi, M.; Vasar, V.; Hion, T.; Eller, T.; Shlik, J. (2001). Sleep-related breathing disorders and daytime complaints. Eesti Arst, Lisa 3, 64.
1.1.
2000
Koks, S.; Mannisto, PT.; Bourin, M.; Shlik, J.; Vasar, V.; Vasar, E. (2000). Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Journal of Psychiatry & Neuroscience, 25 (1), 33−42.
1.1.
2000
Pakriev, S.; Vasar, V.; Aluoja, A.; Shlik, J. (2000). Prevalence of social phobia in the rural population of Udmurtia. Nordic Journal of Psychiatry, 54 (2), 109−112.
1.1.
2000
Veldi, M.; Vasar, V.; Vain, A.; Hion, T.; Kull, M. (2000). Computerized endopharyngeal myotonometry (CEM): A new method to evaluate the tissue tone of the soft palate in patients with obstructive sleep apnoea syndrome. Journal of Sleep Research, 9 (3), 279−284.
1.1.
2000
Toomaspoeg, L.; Toomla, O.; Saarma, M.; Vasar, V. (2000). Influence of ethanol on CD2 receptors of lymphocytes in alcohol dependent inpatients and healthy individuals. Nordic Journal of Psychiatry, 54 (4), 287−291.
1.2.
2000
Veldi, M.; Hion, T.; Vasar, V.; Kull, M.; Vain, A. (2000). Myotonometry reveals changes in the biomechanical properties of the genioglossal muscle in patients with sleep apnoea. Journal of Sleep Research, 9, 200.
1.2.
2000
Veldi, M.; Kull, M.; Vasar, V.; Hion, T.; Vain, A. (2000). Soft palate tone in young and middle-aged apnoeics. Journal of Traffic Medicine , 28 (25), 69.
5.1.
2000
Aluoja, A.; Shlik, J.; Vasar, V. (2000). Symptoms of depression and anxiety in Estonia: Prevalence, coexistence and relationship to the quality of life. Nordic Journal of Psychiatry, 54, 14−15.
5.2.
2000
Hion, T.; Aluoja, A.; Veldi, M.; Shlik, J.; Vasar, V. (2000). Prevalence of symptoms of Insomnia in Estonia. Journal of Sleep Research, 9, 81.
1.1.
1999
Toomaspoeg, L.; Toomla, O.; Saarma, M.; Vasar, V. (1999). Influence of ethanol on E-rosette formation by T lymphocytes in alcoholics - Preliminary report. Nordic Journal of Psychiatry, 53 (1), 69−71.
1.1.
1999
Aluoja, A.; Shlik, J.; Vasar, V.; Luuk, K.; Leinsalu, M. (1999). Development and psychometric properties of the Emotional State Questionnaire, a self-report questionnaire for depression and anxiety. Nordic Journal of Psychiatry, 53 (6), 443−449.
1.1.
1998
Pakriev, S.; Vasar, V.; Aluoja, A.; Saarma, M.; Shlik, J. (1998). Prevalence of mood disorders in the rural population of Udmurtia. Acta Psychiatrica Scandinavica, 97 (3), 169−174.
1.1.
1998
Pakriev, S.; Vasar, V.; Aluoja, A.; Shlik, J. (1998). Prevalence of ICD-10 harmful use of alcohol and alcohol dependence among the rural population in Udmurtia. Alcohol and Alcoholism, 33 (3), 255−264.
1.1.
1998
Marandi, T.; Vasar, V.; Rago, L. (1998). The patterns of use of antidepressants in Estonia in 1996. Nordic Journal of Psychiatry, 52 (6), 465−473.
1.3.
1998
Veldi, M.; Vasar, V.; Hion, T. (1998). Norskamise ja uneapnoe sündroomi tänapäevane ravimeetod - CPAP. Eesti Arst, 77 (4), 331−334.
1.1.
1997
Aluoja, A.; Shlik, J.; Vasar, V.; Kingisepp, PH.; Jagomagi, K.; Vasar, E.; Bradwejn, J. (1997). Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatry Research, 66 (1), 59−67.
1.1.
1997
Shlik, J.; Vasar, V.; Aluoja, A.; Kingisepp, PH.; Jagomagi, K.; Vasar, E.; Rago, L.; Bradwejn, J. (1997). The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biological Psychiatry, 42 (3), 206−212.
1.1.
1997
Pakriev, S.; Vasar, V.; Aluoja, A.; Saarma, M.; Shlik, J. (1997). Screening for depression in the rural population in Udmurtia. Nordic Journal of Psychiatry, 51 (5), 325−330.
1.1.
1997
Shlik, J.; Aluoja, A.; Vasar, V.; Vasar, E.; Podar, T.; Bradwejn, J. (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry & Neuroscience, 22 (5), 332−340.
3.2.
1997
Aluoja, A.; Vasar, V. (1997). Sozialpsychologische Faktoren bei Depressionen. Rosendahl W.; Hennig H.; Saarma M.. Entwicklungen und Tendenzen in der Medizinischen Psychologie – ein Leitfaden (140−149).. Pabst Science Publishers.
1.1.
1994
Vasar, V.; Appelberg, B.; Rimon, R.; Selvaratnam, J. (1994). The effect of fluoxetine on sleep - a longitudinal, double-blind polysomnographic study of healthy-volunteers. International Clinical Psychopharmacology, 9 (3), 203−206.
12.04.2020

Veiko Vasar

https://www.etis.ee/CV/Veiko_Vasar/eng
16.01.1956
7.03.2015

Career

Institutions and positions
01.01.2000–...   
Psychiatry Clinic of Tartu University Hospital, Head of the Clinic
01.09.2004–31.08.2009   
University of Tartu, Faculty of Medicine, Department of Psychiatry, Professor of Psychiatry (1,00)
1999–2004   
University of Tartu, Faculty of Medicine, Department of Psychiatry, Professor (1,00)
1990–1999   
University of Tartu, Faculty of Medicine, Department of Psychiatry, Associate Professor (1,00)
01.01.1990–31.12.1991   
Research fellow, Department of Psychiatry, University of Helsinki
1985–1990   
University of Tartu, Faculty of Medicine, Department of Psychiatry, Assistant (1,00)
1980–1985   
University of Tartu, Faculty of Medicine, Department of Psychiatry, Researcher (1,00)
 
 
Education
1973–1979   
University of Tartu, Faculty of Medicine, M.D.
 
 
R&D related managerial and administrative work
2002−...   
Member of the expert commission of psychiatry (Ministry of Social Affairs);
1992−...   
Member of the Council of the Faculty of Medicine;
1992−...   
Member of the board of the Estonian Association of Psychiatrists;
2003−2006   
Member of the Council of Estonian Scientific Foundation;
2001−2003   
Member of the council of the University of Tartu

Qualifications

Fields of research
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; SPECIFICATION: Neurobiology of sleep, anxiety and mood disorders Epidemiology and psychosocial factors associated with anxiety and mood disorders
 
 
Additional information
Ph.D., medicine
University of Tartu, 1987

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2012
Tõru, I.; Maron, E.; Raag, M.; Vasar, V.; Nutt, D.J.; Shlik, J. (2012). The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers. European Neuropsychopharmacology, 23 (7), 645−652.10.1016/j.euroneuro.2012.08.011.
1.1.
2012
Koido, Kati; Traks, Tanel; Balõtšev, Roman; Eller, Triin; Must, Anne; Kõks, Sulev; Maron, Eduard; Tõru, Innar; Shlik, Jakov; Vasar, Veiko; Vasar, Eero (2012). Associations between LSAMP gene polymorphisms and major depressive disorder and panic disorder. Translational Psychiatry, 2, 1−5.10.1038/tp.2012.74.
5.2.
2012
Luuk, Kersti; Aluoja, Anu; Vasar, Veiko (2012). Childhood adversity and anxiety and depressive symptoms in adulthood: The mediating role of locus of control.
1.1.
2011
Maron, E.; Toru, I.; Hirvonen, J.; Tuominen, L.; Lumme, .V; Vasar, V.; Shlik, J.; Nutt, D.J.; Helin, S.; Någren, K.; Tiihonen, J.; Hietala, J. (2011). Gender differences in brain serotonin transporter availability in panic disorder. Journal of Psychopharmacology, 25 (7), 952−959.10.1177/0269881110389207.
1.3.
2011
Klienberg, A.; Jaanson, P.; Lehtmets, A.; Aluoja, A.; Vasar, V.; Suija, K.; Ööpik, P. (2011). Depressiooni ravijuhend perearstidele. Eesti Arst, 90 (9), 431−446.
5.2.
2011
Vaher, H.; Veldi, M.; Eller, T.; Kasenõmm, P.; Vasar, V. (2011). The predictive value of pediatric sleep health on pediatric behavior. Sleep Medicine, 12. Suppl.1, S129.
5.2.
2011
Veldi, M.; Vaher, H.; Tamm, M.; Torma, T.; Eller, T.; Vasar, V. (2011). Effect of contineous airway pressure treatment on sympathetic nervous activity and daytime function in patients with obstructive sleep apnea. Sleep Medicine, 12. Suppl. 1, S106.
6.6.
2011
Klienberg, A.; Jaanson, P.; Lehtmets, A.; Aluoja, A.; Vasar, V.; Suija, K.; Ööpik, P. (2011). Depressiooni ravijuhis perearstidele. Perearst, 63 (9), 22−64.
1.1.
2010
Kleinberg, A.; Aluoja, A.; Vasar, V. (2010). Point prevalence of major depression in Estonia. Results from the 2006 Estonian Health Survey. European Psychiatry, 25 (8), 485−490.10.1016/j.eurpsy.2010.06.005.
1.1.
2010
Tõru, I.; Aluoja, A.; Võhma, Ü.; Raag, M.; Vasar, V.; Maron, E.; Shlik, J. (2010). Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Psychiatry Research, 178 (2), 342−347.10.1016/j.psychres.2010.04.003.
1.1.
2010
Võhma, Ü.; Aluoja, A.; Vasar, V.; Shlik, J.; Maron, E. (2010). Evaluation of personality traits in panic disorder using Swedish universities Scales of Personality. Journal of Anxiety Disorders, 24 (1), 141−146.
1.1.
2010
Eller, T; Metsküla, K; Talja, I; Maron, E; Uibo, R; Vasar, V. (2010). Thyroid autoimmunity and treatment response to escitalopram in major depression. Nordic Journal of Psychiatry, x−x.
1.1.
2010
Koido, K.; Eller, T.; Kingo, K.; Kõks, S.; Traks, T.; Shlik, J.; Vasar, V; Vasar, E.; Maron, E. (2010). Interleukin 10 family gene polymorphisms are not associated with major depressive disorder and panic disorder phenotypes. Journal of Psychiatric Research, 44 (5), 275−277.10.1016/j.jpsychires.2009.09.001.
1.1.
2010
Maron, E.; Kallassalu, K.; Tammiste, A.; Kolde, R.; Vilo, J.; Tõru, I.; Vasar, V.; Shlik, J.; Metspalu, A. (2010). Peripheral Gene Expression Profiling of CCK-4-Induced Panic in Healthy Subjects. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics, 153B (1), 269−274.10.1002/ajmg.b.30898.
1.2.
2010
Veldi, M.; Ani, R.; Vaher, H.; Eller, T.; Hion, T.; Aluoja, A.; Vasar, V. (2010). Obstructive sleep apnea syndrome (OSAS): Pathophysiology in Estonians. Pathophysiology, 17 (3), 219−223. DOI: 10.1016/j.pathophys.2010.01.001.
1.3.
2010
Maron, E.; Eller, T.; Vasar, V. (2010). Bupropioonravi depressiooni korral: mono- ja kombinatsioonteraapia. Eesti Arst, 89, 113−119.
1.3.
2010
Eller, T.; Maron, E.; Vasar, V. (2010). Depressioon, antidepressantravi ja tsütokiinid. Eesti Arst, 825−832.
1.3.
2010
Vaher, H; Veldi, M; Müürsepp, P; Kasenõmm, P; Vasar, V. (2010). Obstruktiivse uneapnoe sündroomi riskitegurid võivad pärineda lapse- ja noorukieast. Haigusjuhu kirjeldus. Eesti Arst, 746−750.
5.2.
2010
Maron, E., Tõru, I., Hirvonen, J., Vasar, V., Shlik, J., Nutt, D.J., Tiihonen, J., Hietala, J. (2010). Brain serotonin transporter availability in panic disorder: Gender differences and implications for treatment response to escitalopram. In: (45−45).27th CINP Congress; Hong Kong 2010-06-06 to 2010-06-10. Elsevier.
1.1.
2009
Eller, T.; Aluoja, A.; Maron, E.; Vasar, V. (2009). Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina-Lithuania, 45 (12), 971−977.
1.1.
2009
Maron, E.; Eller, T.; Vasar, V.; Nutt, D.J. (2009). Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. Journal of Clinical Psychiatry, 70 (7), 1054−1056.
1.1.
2009
Eller, T.; Vasar, V.; Shlik, J.; Maron, E. (2009). The role of IL-2 and soluble IL-2R in depression and antidepressant response. Current Opinion in Investigational Drugs, 10 (7), 638−643.
1.1.
2009
Maron, E.; Tammiste, A.; Kallassalu, K.; Eller, T.; Vasar, V.; Nutt, D.J.; Metspalu, A. (2009). Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European Neuropsychopharmacology, 19, 6, 451−456.
1.1.
2009
Maron, E.; Tõru, I.; Mäemets, K.; Sepp, S.; Vasar, V.; Shlik, J.; Zharkovski, A. (2009). CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects. Journal of Psychopharmacology, 23 (4), 460 −464. DOI: 10.1177/0269881108089600.
1.3.
2009
Maron, E; Eller, T; Nutt, D; Vasar, V. (2009). Bupropiooni augmentatsiooni toime estsitalopraamravi suhtes resistentsetel depressiivsetel patsientidel. Eesti Arst, 88, 82−90.
5.2.
2009
Vaher, H.; Vasar, V.; Ani, R.; Veldi, M. (2009). Treatment of sleepapnea in cases of Prader-Willi syndrome. Sleep Medicine, 10. p. S43. (2).
1.1.
2008
Maron, E.; Tõru, I.; Tasa, G.; Must, A.; Toover, E.; Lang, A.; Vasar, V.; Shlik, J. (2008). Association testing of panic disorder candidate genes using Cck-4 challenge in healthy volunteers. Neuroscience Letters, 446, 88−92. DOI: 10.1016/j.neulet.2008.09.052.
1.1.
2008
Eller, T.; Vasar, V.; Shlik3, J.; Maron, E. (2008). Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32 (2), 445−450. DOI: 10.1016/j.pnpbp.2007.09.015.
1.2.
2008
Veldi, M.; Vain, A.; Vasar, V.; Kull, M.; Partinen, M. (2008). Restless legs syndrome (RLS) and muscular tone of tibial muscle. Sleep and Biological Rhythms, 6 (4), 242−248. DOI: 10.1111/j.1479-8425.2008.00365.x.
1.3.
2008
Kõrv, J.; Linnamägi, Ü.; Asser, T.; Vasar, V.; Eamets, R.; Sobocki, P. (2008). Kui suured on kulutused peaajuhaigustele Eestis? Eesti Arst, 87 (5), 347−355.
1.1.
2007
Maron, E.; Tõru, I.; Must, A.; Tasa, G.; Toover, E.; Vasar, V.; Lang, A.; Shlik, J. (2007). Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. Neuroscience Letters, 411 (3), 180−184.
5.1.
2007
Maron, E., Yuan, P., Tõru, I., Vasar, V., Neumeister, A., Shlik, J., Manji, H. (2007). Associations between plasma BDNF and CCK-4 challenge in healthy subjects. European neuropsychopharmacology, 17: ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe Nice, FRANCE, MAR 08-11, 2007. Elsevier, 8−9. (Suppl. 1).
5.2.
2007
Eller, T.; Metsküla, K.; Talja, I.; Vasar, V.; Uibo, R. (2007). Uurimus autoantikehade esinemisest depressiivsetel haigetel. Eesti Arst, 86 (9), 672−673.
5.2.
2007
Veldi, M.; Eller, T.; Hion, T.; Pindmaa, M.; Ani, R.; Kull, M.; Partinen, M.; Vasar, V. (2007). Ageing, sleep apnea, upper airway disorders, cardiac disorders, and symptoms of depression. Sleep Medicine, 8, S87.
5.2.
2007
Veldi, M.; Partinen, M.; Torma, T.; Vasar, V.; Kull, M. (2007). Nocturnal groaning: parasomnia related to REM-sleep. Sleep Medicine, 8, S87.
5.2.
2007
Veldi, M.; Vain, A.; Vasar, V.; Kull, M.; Partinen, M. (2007). Restless legs syndrome and changes of muscular tone. Sleep Medicine, 8, S86.
5.2.
2007
Veldi, M.; Hion, T.; Vasar, V.; Kull, M. (2007). Quality of life and driving ability in sleep apnoea patients before and after CPAP treatment - evaluation by sleep and daytime habits questionnaire and divided attention steering simulator (DASS). Sleep and Biological Rhythms, 5, A6.
1.1.
2006
Eller, T.; Aluoja, A.; Vasar, V.; Veldi, M. (2006). Symptoms of anxiety and depression in Estonian medical students with sleep problems. Depression and Anxiety, 23 (4), 250−256.
1.1.
2006
Tõru, I.; Shlik, J.; Maron, E.; Vasar, V.; Nutt, D. (2006). Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology, 186 (1), 107−112.
5.1.
2006
Maron, E.; Koido, K.; Must, A.; Reimets, A.; Kõks, S.; Vasar, E.; Vasar, V.; Shlik, J. (2006). Association study of limbic system-associated membrane protein gene polymorphisms in panic disorder. European neuropsychopharmacology, 16 (Suppl. 4). 459−460.
1.1.
2005
Maron, E.; Lang, A.; Tasa, G.; Liivlaid, L.; Toru, I.; Must, A.; Vasar, V.; Shlik, J. (2005). Associations between serotonin-related gene polymorphisms and panic disorder. International Journal of Neuropsychopharmacology, 8 (2), 261−266.
1.1.
2005
Veldi, M.; Aluoja, A.; Vasar, V. (2005). Sleep quality and more common sleep-related problems in medical students. Sleep Medicine, 6 (3), 269−275.
1.1.
2005
Maron, E.; Nikopensius, T.; Koks, S.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Koido, K.; Kurg, A.; Metspalu, A.; Vasar, E.; Vasar, V.; Shlik, J. (2005). Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatric Genetics, 15 (1), 17−24.
1.1.
2005
Koido, K.; Kõks, S.; Nikopensius, T.; Maron, E.; Altmäe, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Kurg, A.; Shlik, J.; Vasar, V.; Metspalu, A.; Vasar, E. (2005). Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. International Journal of Neuropsychopharmacology, 8 (2), 235−244.
3.1.
2005
Veldi, M.; Vasar, V.; Vain, A.; Torma, T.; Kull, M. (2005). Impact of CPAP Treatment on the Muscular Tone of the Tongue. In: Penzel, T.; Fietze, I.; Chokroverty, S. (_EditorsAbbr). Proceedings of the World Association of Sleep Medicine 1st Congress (111−114).. Bologna, Italy: MEDIMOND S.r.l..
5.1.
2005
Maron, E.; Koks, S.; Nikopensius, T.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Koido, K.; Kurg, A.; Shlik, J.; Vasar, V.; Metspalu, A.; Vasar, E. (2005). Association and haplotype analaysis of 90 single-nucleotide polymorphisms in mood disorders. European Neuropsychopharmacology, 15, S55−S56.
5.2.
2005
Eller, T.; Aluoja, A.; Vasar, V.; Veldi, M. (2005). Depressiooni ja ärevuse sümptomid seoses uneprobleemidega eesti arstiüliõpilastel. Eesti Arst, 9, 655.
1.1.
2004
Aluoja, A.; Leinsalu, M.; Shlik, J.; Vasar, V.; Luuk, K. (2004). Symptoms of depression in the Estonian population: prevalence, sociodemographic correlates and social adjustment. Journal of Affective Disorders, 78 (1), 27−35.
1.1.
2004
Maron, E.; Tasa, G.; Toru, I.; Lang, A.; Vasar, V.; Shlik, J. (2004). Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. World Journal of Biological Psychiatry, 5 (3), 149−154.
1.1.
2004
Maron, E.; Kuikka, JT.; Shlik, J.; Vasar, V.; Vanninen, E.; Tiihonen, J. (2004). Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Research-Neuroimaging, 132 (2), 173−181.
1.1.
2004
Shlik, J.; Maron, E.; Toru, I.; Aluoja, A.; Vasar, V. (2004). Citalopram challenge in social anxiety disorder. International Journal of Neuropsychopharmacology, 7 (2), 177−182.
1.1.
2004
Maron, E.; Toru, I.; Vasar, V.; Shlik, J. (2004). The effect of 5-hydroxytryptophan on chotecystokinin-4-induced panic attacks in healthy volunteers. Journal of Psychopharmacology, 18 (2), 194−199.
1.1.
2004
Maron, E.; Kuikka, JT.; Ulst, K.; Tiihonen, J.; Vasar, V.; Shlik, J. (2004). SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. European Archives of Psychiatry and Clinical Neuroscience, 254 (6), 392−396.
1.2.
2004
Veldi, M.; Vasar, V.; Vain, A.; Kull, M. (2004). Obstructive sleep apnea and ageing: Myotonometry demonstrates changes in the soft palate and tongue while awake. Pathophysiology, 11 (3), 159−165.
1.3.
2004
Veldi, M.; Aluoja, A.; Vasar, V. (2004). Une kvaliteet ja sagedasemad unehäired arstiteaduskonna üliõpilastel. Eesti Arst, 83 (2), 76−80.
1.3.
2004
Aluoja, A.; Slik, J.; Vasar, V. (2004). Depressioon ja sotsiaalne toimimine. Eesti Arst, 83 (4), 241−246.
5.1.
2004
Maron, E.; Tasa, G.; Toru, I.; Lang, A.; Vasar, V.; Shlik, J. (2004). Association between serotonin-related genetic polymorphisms and cholecystokinin tetrapeptide induced panic attacks in healthy volunteers. European Neuropsychopharmacology, 14, S125−S126.
5.1.
2004
Maron, E.; Tasa, G.; Toru, I.; Lang, A.; Vasar, V.; Shlik, J. (2004). Association between serotonin-related genetic polymorphisms and cholecystokinin tetrapeptide induced panic attacks in healthy volunteers. European Neuropsychopharmacology, 14, S14−S15.
5.1.
2004
Maron, E.; Nikopensius, T.; Koks, S.; Altmae, S.; Heinaste, E.; Vabrit, K.; Tammekivi, V.; Hallast, P.; Koido, K.; Kurg, A.; Metapalu, A.; Vasar, E.; Vasar, V.; Shlik, J. (2004). Association study of 90 candidate genetic polymorphisms in panic disorder: Positive findings with SNPs in serotonin, cholecystokinin and dopamine related genes. European Neuropsychopharmacology, 14, S317−S317.
5.2.
2004
Veldi, M.; Aluoja, A.; Vasar, V. (2004). Sleep quality and more common sleep-related problems in medical students. Journal of Sleep Research, 13, 770.
5.1.
2003
Maron, E.; Kuikka, JT.; Shlik, J.; Vasar, V.; Vanninen, E.; Tiihonen, J. (2003). Reduced brain serotonin transporter binding in patients with panic disorder. European Neuropsychopharmacology, 13, S358−S359.
1.1.
2002
Veldi, M.; Vasar, V.; Hion, T.; Vain, A.; Kull, M. (2002). Myotonometry demonstrates changes of lingual musculature in obstructive sleep apnoea. European Archives of Oto-Rhino-Laryngology, 259 (2), 108−112.
5.1.
2002
Shlik, J.; Maron, E.; Aluoja, A.; Vasar, V.; Toru, I. (2002). Citalopram challenge in social anxiety disorder. European Neuropsychopharmacology, 12, S339−S340.
6.3.
2002
Kull, M.; Veldi, M.; Vasar, V.; Hion, T. (2002). Obstruktiivse uneapnoe hetkeseis: diagnostika ja ravi põhimõtted. Lege Artis, 5 (9), 26−29.
1.1.
2001
Pakriev, S.; Shlik, J.; Vasar, V. (2001). Course of depression: Findings from a cross-sectional survey in rural Udmurtia. Nordic Journal of Psychiatry, 55 (3), 185−189.
1.1.
2001
Veldi, M.; Vasar, V.; Hion, T.; Kull, M.; Vain, A. (2001). Ageing, soft-palate tone and sleep-related breathing disorders. Clinical Physiology, 21 (3), 358−364.
1.3.
2001
Veldi, M.; Vasar, V.; Hion, T.; Eller, T.; Shlik , J.; Kull , M. (2001). Vanus ja uneapnoehaigus – riskitegurid ja päevased kaebused. Eesti Arst, 80 (8), 325−328.
5.2.
2001
Veldi, M.; Vasar, V.; Hion, T.; Eller, T.; Shlik, J. (2001). Sleep-related breathing disorders and daytime complaints. Eesti Arst, Lisa 3, 64.
1.1.
2000
Koks, S.; Mannisto, PT.; Bourin, M.; Shlik, J.; Vasar, V.; Vasar, E. (2000). Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Journal of Psychiatry & Neuroscience, 25 (1), 33−42.
1.1.
2000
Pakriev, S.; Vasar, V.; Aluoja, A.; Shlik, J. (2000). Prevalence of social phobia in the rural population of Udmurtia. Nordic Journal of Psychiatry, 54 (2), 109−112.
1.1.
2000
Veldi, M.; Vasar, V.; Vain, A.; Hion, T.; Kull, M. (2000). Computerized endopharyngeal myotonometry (CEM): A new method to evaluate the tissue tone of the soft palate in patients with obstructive sleep apnoea syndrome. Journal of Sleep Research, 9 (3), 279−284.
1.1.
2000
Toomaspoeg, L.; Toomla, O.; Saarma, M.; Vasar, V. (2000). Influence of ethanol on CD2 receptors of lymphocytes in alcohol dependent inpatients and healthy individuals. Nordic Journal of Psychiatry, 54 (4), 287−291.
1.2.
2000
Veldi, M.; Hion, T.; Vasar, V.; Kull, M.; Vain, A. (2000). Myotonometry reveals changes in the biomechanical properties of the genioglossal muscle in patients with sleep apnoea. Journal of Sleep Research, 9, 200.
1.2.
2000
Veldi, M.; Kull, M.; Vasar, V.; Hion, T.; Vain, A. (2000). Soft palate tone in young and middle-aged apnoeics. Journal of Traffic Medicine , 28 (25), 69.
5.1.
2000
Aluoja, A.; Shlik, J.; Vasar, V. (2000). Symptoms of depression and anxiety in Estonia: Prevalence, coexistence and relationship to the quality of life. Nordic Journal of Psychiatry, 54, 14−15.
5.2.
2000
Hion, T.; Aluoja, A.; Veldi, M.; Shlik, J.; Vasar, V. (2000). Prevalence of symptoms of Insomnia in Estonia. Journal of Sleep Research, 9, 81.
1.1.
1999
Toomaspoeg, L.; Toomla, O.; Saarma, M.; Vasar, V. (1999). Influence of ethanol on E-rosette formation by T lymphocytes in alcoholics - Preliminary report. Nordic Journal of Psychiatry, 53 (1), 69−71.
1.1.
1999
Aluoja, A.; Shlik, J.; Vasar, V.; Luuk, K.; Leinsalu, M. (1999). Development and psychometric properties of the Emotional State Questionnaire, a self-report questionnaire for depression and anxiety. Nordic Journal of Psychiatry, 53 (6), 443−449.
1.1.
1998
Pakriev, S.; Vasar, V.; Aluoja, A.; Saarma, M.; Shlik, J. (1998). Prevalence of mood disorders in the rural population of Udmurtia. Acta Psychiatrica Scandinavica, 97 (3), 169−174.
1.1.
1998
Pakriev, S.; Vasar, V.; Aluoja, A.; Shlik, J. (1998). Prevalence of ICD-10 harmful use of alcohol and alcohol dependence among the rural population in Udmurtia. Alcohol and Alcoholism, 33 (3), 255−264.
1.1.
1998
Marandi, T.; Vasar, V.; Rago, L. (1998). The patterns of use of antidepressants in Estonia in 1996. Nordic Journal of Psychiatry, 52 (6), 465−473.
1.3.
1998
Veldi, M.; Vasar, V.; Hion, T. (1998). Norskamise ja uneapnoe sündroomi tänapäevane ravimeetod - CPAP. Eesti Arst, 77 (4), 331−334.
1.1.
1997
Aluoja, A.; Shlik, J.; Vasar, V.; Kingisepp, PH.; Jagomagi, K.; Vasar, E.; Bradwejn, J. (1997). Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatry Research, 66 (1), 59−67.
1.1.
1997
Shlik, J.; Vasar, V.; Aluoja, A.; Kingisepp, PH.; Jagomagi, K.; Vasar, E.; Rago, L.; Bradwejn, J. (1997). The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biological Psychiatry, 42 (3), 206−212.
1.1.
1997
Pakriev, S.; Vasar, V.; Aluoja, A.; Saarma, M.; Shlik, J. (1997). Screening for depression in the rural population in Udmurtia. Nordic Journal of Psychiatry, 51 (5), 325−330.
1.1.
1997
Shlik, J.; Aluoja, A.; Vasar, V.; Vasar, E.; Podar, T.; Bradwejn, J. (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry & Neuroscience, 22 (5), 332−340.
3.2.
1997
Aluoja, A.; Vasar, V. (1997). Sozialpsychologische Faktoren bei Depressionen. Rosendahl W.; Hennig H.; Saarma M.. Entwicklungen und Tendenzen in der Medizinischen Psychologie – ein Leitfaden (140−149).. Pabst Science Publishers.
1.1.
1994
Vasar, V.; Appelberg, B.; Rimon, R.; Selvaratnam, J. (1994). The effect of fluoxetine on sleep - a longitudinal, double-blind polysomnographic study of healthy-volunteers. International Clinical Psychopharmacology, 9 (3), 203−206.
12.04.2020

Otsi projekti

  • {{item.Name}}
Asutus on projekti finantseerija   Asutus on projekti teostaja  
  • {{searchListItem.Name}}
Kõik   Tavaprojektid   Ülemprojektid   Alamprojektid  
Uus Frascati (2015)
Uus ja vana Frascati (otsing uue järgi väljastab ka seotud vanad)
Kõik
Käimasolevad
Lõppenud
Algus
Hajus
Täpne
Lihtotsing Tühjenda
  • Leitud 7 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
ETFETF5842CPAP-ravi mõju uneapnoehaigete psühhosomaatilisele seisundile ning pehmesuulae ja keelelihastoonusele01.01.200431.12.2007Marlit VeldiTartu Ülikool, Arstiteaduskond36 028,42 EUR
SFSF0182590As03Psüühikahäirete epidemioloogia, geneetilised tegurid ja patogeneesi mehhanismid01.01.200331.12.2007Veiko VasarTartu Ülikool, Arstiteaduskond246 251,58 EUR
MUUMARPS04059Serotoniini depletsioon ja kalduvus paanikahoogudele paanikahäirega patsientidel. Serotonin depletion and vulnerability to panic attacks in panic disorder01.02.200328.02.2005Veiko VasarTartu Ülikool35 711,40 EUR
IUTIUT20-45Skisofreenia ja meeleoluhäirete ravivastust ennustavad neurobioloogilised, geneetilised ja psühholoogilised markerid01.01.201431.12.2019Eduard MaronTartu Ülikool, Meditsiiniteaduste valdkond, kliinilise meditsiini instituut634 200,00 EUR
SFSF0180125s08Skisofreenia, meeleolu- ja paanikahäirete tekke, patogeneesi ja ravitulemustega seotud neurobioloogilised, geneetilised ja psühhosotsiaalsed tegurid.01.01.200831.12.2013Veiko VasarTartu Ülikool, Arstiteaduskond403 208,02 EUR
ETFETF7034SSTP ravivastust ennustavad geneetilised faktorid paanikahäirega haigetel01.01.200731.12.2010Eduard MaronTartu Ülikool, Arstiteaduskond57 024,27 EUR
APSF0180125s08AP11Väikesemahulise teaduse infrastruktuuri kaasajastamine teadusteema SF0180125s08 raames01.01.201131.12.2011Veiko VasarTartu Ülikool, Arstiteaduskond34 001,00 EUR